The ? The peroxisome !
For several years, the history of Apteeus has led us to specialize in techniques for…
8.8 million euros for accelerated drug repurposing for rare neurological disorders
APTEEUS has received funding from the frontiers in Research Fund (NFRF) – 2022 Horizon Global…
In 2023, we will again associate empathy and humanity with our discoveries and our achievements. Apteeus wish you the best!
2023 is an important year for Apteeus. Our role as scientific support and our integration…
15th edition of the Rare Disease Day
On the occasion of the 15th edition of the Rare Diseases awareness campaign which took…
The beginning of clofoctol story in covid19
You will read why we decided to run clinical trials with clofoctol in covid19… Large…
HERE WE ARE, THE CLOFOCTOL TRIAL IN COVID19 WILL BEGIN!
The entire Apteeus team is delighted with this news. After months of fundraising, designing the…
Personalized research delivered a candidate therapy for Calixte, Satine, Adeline and others
“Thanks to a technology based on mass spectrometry, we were able, in less than 10…
CoViD project, the clinical trial became a national priority
Since March 2020, we have been working on the repositioning of a drug against CoViD19,…
A new European policy framework for Rare Disorders
We are happy to find Apteeus’ commitments among the 8 recommendations of Rare2030: establish partnerships…
Why is #Apteeus engaged in research against the # COVID19 pandemic?
Responding quickly to an important medical need has been the commitment of APTEEUS for several…